Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with <sup>90</sup>Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI

<div>Standardized therapy and study timeline. This therapy and study cycle was repeated with a mean interval of 10 weeks (T<sub>3</sub> and T<sub>4</sub>). In 3 of 20 patients, <sup>90</sup>Y/<sup>111</sup>In-DOTATOC was replaced by <sup>177</sup>Lu-DOTATOC in the second session because of deterioration of kidney function.</div>

Contrast Media & Molecular Imaging

fig1

Figure 1

Figure 1: Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with <sup>90</sup>Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI 

Figure 1 | Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI 